|Industry||Pharmaceuticals, Drugs & Healthcare|
|Headquarters||Mumbai, Maharashtra, India|
Yogesh Agrawal, Managing Director.Rajesh Agrawal, Joint Managing Director
|Products||Branded Generic Formulations / Medicines|
|Revenue||₹1,705 crore (US$270 million) (2015–2016)|
Number of employees
Ajanta Pharma (Mauritius) Ltd, Ajanta Pharma Philippines Inc., Ajanta Pharma USA Inc.,Ajanta Pharma Nigeria Ltd.
Ajanta Pharma Limited (APL) (BSE: 532331 | NSE: AJANTPHARM) is an Indian multinational, engaged in development, manufacturing and marketing of pharmaceutical formulations. It has presence in India, USA and about 30 Emerging countries including Africa, Philippines, Rest of Asia, Middle East and CIS. Established in 1973.
Key Markets & Business
Company has over 1,400 products registered currently in various countries and equal number of products are under approval.
In India, company is a branded generic player focused on few high growth specialty therapies of Ophthalmology, Dermatology, Cardiology and Pain Management.
Company exports products to over 30 countries in Asia and Africa. In these markets, company serves a wide range of therapeutic segments of Anti Malaria, Cardio, GI, Antibiotic, Derma, Anti Histamine, Multivitamin, Gynaec, Pain Management, etc.
Company has recently stepped up its presence in the USA with a select product portfolio, which includes niche and complex technology products. Currently company has 12 products launched in the market and many more awaiting launches. Company has a firm product pipeline under development for the USA market and expect to file about 12-15 ANDAs every year with US FDA.
Ajanta Pharma operates 7 manufacturing facilities; 6 within India and 1 in Mauritius. In India, 5 facilities manufacture finished formulations, including Dahej plant which is successfully inspected by US FDA and Guwahati plant which caters to domestic and emerging markets. Another 1 plant manufactures Active Pharmaceutical Ingredients (APIs) primarily for captive consumption.